SFA Therapeutics
New accelerator entry · 2021-06-18 · the record
In their words
SFA Therapeutics is creating therapeutically-tailored oral drugs that regulate the immune system; with a focus on autoimmune diseases and cancers that originate from chronic inflammation. There are over 300 million patients who suffer from autoimmune diseases. Our treatment is designed to block the root cause of many of these chronic inflammatory diseases, with safe oral drugs. We have strong clinical data from a phase 1b clinical trial in psoriasis, and human data in pancreatic cancer, uveitis and NASH. we have a total of 9 drugs in our pipeline and 15 patents.
What the record says
The full profile
Source Check, INVEST, RECRUIT and Press Requests on SFA Therapeutics
- Source Check — verify what SFA Therapeutics states, against the registers that hold it.
- INVEST — size up this company on the figures its record states.
- RECRUIT — see who is already on the team.
- Press Requests — connect with SFA Therapeutics for a story.
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist SFA TherapeuticsYou get an alert in MentionFox the next time this company shows up.
Is this you?
If you're behind SFA Therapeutics: acceptance into a YC batch is one of the few weeks a young company gets looked up by people who matter — investors, other founders, press. FoxPlug turns the commits, deploys, and releases you're already making into that story automatically, so anyone who looks finds something current. FoxChat puts a guide on your own site so the people YC's own page just sent you don't read one line and leave.
Sourced from the company's Y Combinator directory entry.